Epidemiologie und Prävention des Oropharynxkarzinoms

HNO, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 30, 2025

Language: Английский

---

Evolution of testing for the diagnosis of human papillomavirus (HPV) status in head and neck squamous cell carcinoma: Where from and where to?

Oral Oncology, Journal Year: 2025, Volume and Issue: 162, P. 107208 - 107208

Published: Feb. 2, 2025

Language: Английский

---

Efficacy of oral rinse and other detection methods in detecting oral human papillomavirus infections: the Oromouth cohort study

Journal of Infection, Journal Year: 2025, Volume and Issue: unknown, P. 106438 - 106438

Published: Feb. 1, 2025

Highlights•Oral rinse is the most common measure for estimating oral HPV prevalence.•We compared to pharyngeal wall and tongue base brushes, & tonsil tissue.•Combining all four sites, any HR-HPV prevalence were 18% 4.3%.•Oral misses 73% (11/15) of cases detected by other sites.•All 4 sample types combined improves detection over alone 38%.AbstractObjectivesHuman papillomavirus (HPV) mediated oropharyngeal cancer (OPC) incidence has increased dramatically. Accurate data are essential assessing population epidemiology, vaccination screening programmes. As commonly used primary outcome prevalence, we aimed compare efficacy against methods.MethodsThe Oromouth study enrolled 945 participants, aged 0-65 years (63% female), undergoing tonsillectomy non-malignant indications, without OPC diagnoses. Samples from rinse, wall, base, tissue blood collected. DNA in samples was centrally tested via polymerase chain reaction, serology antibodies. Statistical analyses assessed rates ratios.ResultsCombining collection high-risk (HR)-HPV 4·3% 18%, respectively. similar between males (4·1%) females (4·5%). Oral had highest (4·0%) (16%), but still missed identified as HR-HPV-positive sites. Compared alone, an additional 38% (11/29) infections picked up three methods. Addition testing did not result substantial improvement.ConclusionsOf demonstrates far important limitations. These findings should be taken into consideration when infection rates, especially studies

Language: Английский

---

Development of a multiplexed lateral flow assay for the serologic detection of HPV-associated head and neck cancer

Cancer Biomarkers, Journal Year: 2025, Volume and Issue: 42(2)

Published: Feb. 1, 2025

Background Among head and neck squamous cell carcinomas (HNSCCs), the incidence of oropharyngeal cancer (OPC) has been increasing in recent decades. Human papillomavirus (HPV) type 16 is associated with majority OPC. Circulating antibodies (Abs) to multiple HPV16 early antigens, including E2, E6, E7, have detected patient sera, are strongly risk for However, HPV serology currently requires laboratory-based tests that difficult implement large-scale screening. Objective The goal this study was develop validate a point-of-care assay rapid detection circulating IgG antigens. Methods We measured Abs E7 proteins using lateral flow (LFA) sera from 119 newly diagnosed OPC cases, 41 partners, 81 healthy volunteers. patients HPV-OPC were classified as HPV-positive based on situ hybridization (ISH) or institutional p16 immunohistochemistry. sensitivity specificity LFA determined by comparing clinical diagnosis. Results each individual 95.1% (77/81), 96.3% (78/81), 98.7% (80/81), respectively. sensitivities follows: 47.9% (57/119), 31.9% (38/119), 57.1% (68/119). 3-biomarker panel (at least one positive Abs) demonstrated 76.5% (91/119) 92.6% (75/81). Conclusions developed multiplexed serologic responses HPV16. Further research required determine utility these + HNSCC screening, higher specificity, an assessment benefits test results yet be evaluated context.

Language: Английский

---

Blood‐based biomarkers of human papillomavirus–associated cancers: A systematic review and meta‐analysis

Cancer, Journal Year: 2020, Volume and Issue: 127(6), P. 850 - 864

Published: Dec. 3, 2020

Background Despite the significant societal burden of human papillomavirus (HPV)–associated cancers, clinical screening interventions for HPV‐associated noncervical cancers are not available. Blood‐based biomarkers may help close this gap in care. Methods Five databases were searched, 5687 articles identified, and 3631 unique candidate titles abstracts independently reviewed by 2 authors; 702 underwent a full‐text review. Eligibility criteria included assessment blood‐based biomarker within cohort or case‐control study. Results One hundred thirty‐seven studies included. Among all assessed, HPV‐16 E seropositivity circulating HPV DNA most significantly correlated with comparison cancer‐free controls. In scenarios, E6 varied nonsignificantly according to tumor type, specimen collection timing, anatomic site (crude odds ratio [cOR] p16+ HPV+ oropharyngeal cancer [OPC], 133.10; 95% confidence interval [CI], 59.40‐298.21; cOR HPV‐unspecified OPC, 25.41; CI, 8.71‐74.06; prediagnostic 59.00; 15.39‐226.25; cervical cancer, 12.05; 3.23‐44.97; anal 73.60; 19.68‐275.33; penile 16.25; 2.83‐93.48). Circulating was valid (cOR, 15.72; 3.41‐72.57). 3 studies, cases exhibited microRNA expression profiles Other assessed candidates valid. Conclusions antibodies robustly analyzed promising date. Comparative validity analyses warranted. Variations type–specific, high‐risk prevalence world region highlight need targeting more types. Further investigation profiling appears indicated.

Language: Английский

---